Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab

Haematologica. 2020 Jul;105(7):e382-e383. doi: 10.3324/haematol.2020.253849.

Authors

Arnon P Kater¹, Yanwen Jiang², Brenda Chyla³, John F Seymour⁴

Affiliations

¹ Department of Hematology, Amsterdam University Medical Centers, Location AMC, Amsterdam, on behalf of Hovon CLL Working Group, Amsterdam, the Netherlands a.p.kater@amc.uva.nl.
² Genentech, Inc., South San Francisco, CA, USA.
³ AbbVie, North Chicago, IL, USA.
⁴ Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Baculoviral IAP Repeat-Containing 3 Protein
Bridged Bicyclo Compounds, Heterocyclic
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Mutation
Rituximab
Sulfonamides

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Rituximab
BIRC3 protein, human
Baculoviral IAP Repeat-Containing 3 Protein
venetoclax